ClinicalTrials.gg
Active, not recruitingNCT04150497Updated Nov 9, 2026

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

A Phase 1/2 interventional study of UCART22 and CLLS52 in B-cell Acute Lymphoblastic Leukemia, sponsored by Cellectis S.A.. Active, not recruiting at 20 sites in 2 countries. Open to participants aged 12 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Cellectis S.A. · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 9, 2026Now Active, not recruitingPrimary completion moved+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
12 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 725 studies in Burkitt Lymphoma with a site in United States — 70 open to participants now, 118 under way, 10 of them phase 3. Burkitt Lymphoma · United States.

Enrollment
242nd of 594
45 · median 37
Started
2019
with 19 others
Phase 1/2
83 of 725
14 open now
Primary completion
2026-09
later than 29 of 117 live
Registered
634th of 725
by date

Among the 725 studies in Burkitt Lymphoma with a site in United States, this one is the 242nd largest by enrollment of the 594 interventional ones that give a count, is one of 20 that started in 2019, is one of 83 in phase 1/2, reaches primary completion later than 29 of the 117 other live ones, and was the 634th registered.

Burkitt Lymphoma

978 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

70 of the 725 studies in Burkitt Lymphoma with a site in United States are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 132 Burkitt Lymphoma studies recruiting now, 41 (31%) set no upper age limit and 78 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 12 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 725 studies in Burkitt Lymphoma with a site in United States, or all of them as a file.
02

Study summary

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to determine the optimal dose of CLLS52 as part of the FCA LD regimen followed by the Recommended Phase 2 Dose (RP2D) of UCART22 and evaluate the safety and efficacy of UCART22.

03

Conditions studied

  • B-cell Acute Lymphoblastic Leukemia

Keywords

  • B-cell Acute Lymphoblastic Leukemia (B-ALL)
  • Relapse/Refractory B-ALL
  • Universal Chimeric Antigen Receptor T-Cell (UCAR-T) Therapy
  • Allogeneic
  • Transcription Activator-Like Effector Nuclease (TALEN®)
04

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
12 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have measurable or evaluable disease in the bone marrow (BM) of at least 5% blasts at the time of enrollment
  • Received prior autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy (unless participants were not able to receive prior autologous anti-CD19 CAR T-cell therapy or if autologous anti-CD19 CAR T-cell therapy has not been available due to any reason or documented as CD19 negative B-ALL.

Cohort A:

- At least 70% of B-ALL blast cells must express CD22 by flow cytometry performed as per standard practice

Cohort B:

- Less than 70% of B-ALL blast cells must express CD22 by flow cytometry performed as per standard practice

Exclusion criteria

Exclusion Criteria:

  • Prior CD22 CAR-T cell therapy
  • More than 1 allogenic hematopoietic stem cell transplant ()
  • Active, acute, or chronic (GvHD)
  • White blood cell (WBC) count ≥ 50,000 cells/μL at Screening or rapidly progressive disease (PD) that, in the estimation of the Investigators and Sponsor, would compromise ability to complete study therapy
  • Radiologically detected central nervous system (CNS) leukemia or CNS-3 disease
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    UCART22

    Phase 1 Dose Escalation: Several tested doses of UCART22 until the Maximum Tolerated Dose (MTD) is identified and establish RP2D. Phase 2 Part 1 Dose Optimization: Two doses of CLLS52 followed by RP2D of UCART22. Phase 2 Part 2 Dose Expansion: Optimal dose of CLLS52 followed by RP2D of UCART22.

    Biological: UCART22 · Biological: CLLS52

Interventions

  • BiologicalUCART22

    Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen

  • BiologicalAlemtuzumabStudies of AlemtuzumabAlemtuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A monoclonal antibody that recognizes a CD52 antigen

    Also known as: Alemtuzumab

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) throughout the study in relation to UCART22 and/or lymphodepletion

    Time frame: 24 months

  2. Percentage of participants achieving a complete response (CR) or CR with incomplete hematologic recovery (CRi) according to the Response Criteria for acute lymphoblastic leukemia (ALL) assessed by independent response review committee

    Time frame: Within 3 months at Day 28, Day 56, Day 84

Secondary outcomes

  1. Duration of Response

    Time frame: From the date of the initial response to the date of disease progression or death from any cause, whichever occurs first, assessed up to 24 months4

  2. Progression Free Survival

    Time frame: From the first day of trial treatment to the date of disease progression or death from any cause, whichever occurs first, assessed up to 24 months

  3. Overall Survival

    Time frame: From the first day of trial treatment to the date of death from any cause, assessed up to 24 months

  4. Pharmacokinetic (PK) profile/exposure levels of CLLS52 (Alemtuzumab) used during lymphodepletion

    Time frame: Lymphodepletion to Day 56

  5. Number of participants who were transplant ineligible at trial start that transition to transplant eligible as assessed by the investigator

    Time frame: UCART22 infusion to Day 84

  6. Number of participants achieving minimal residual disease (MRD) negativity

    Time frame: Day 28, Day 42, Day 56, Day 84

  7. Overall Response Rate (ORR)

    ORR is defined as number of participants who have achieved CR, CRi, complete response with partial hematologic recovery (CRh), and Morphologic Leukemia-Free State (MLFS).

    Time frame: At 3 months (Day 28, Day 42, Day 56, Day 84) as defined by National Comprehensive Cancer Network (NCCN) guidelines

  8. Molecular MRD-negative event free survival (mEFS) rate

    Time frame: At 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months

  9. Changes over time on quality of life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (adults)

    EORTC QLQ-C30, a cancer-specific tool that assesses global health status, functional scales, and symptom burden. The questionnaire provides functional scores (physical, role, cognitive, emotional, and social), symptom scores (fatigue, nausea and vomiting, pain, dyspnoea, sleep disturbance, appetite loss, constipation, diarrhoea, and financial difficulties), and a global quality of life/health status score. Patients provide their responses on a 4-category rating scale for most of the items (not at all, a little, quite a bit, and very much), and on a 7-point numeric rating scale for the global items. Raw scores are converted into scale scores ranging from 0 to 100. For the functional scales and the global scale, higher scores represent better health-related quality of life (HRQoL); whereas for the symptom scales lower scores represent better HRQOL.

    Time frame: 24 months

  10. Changes over time on quality of life using Pediatric Quality of Life Inventory (PedsQL) 4.0 (12-17 years)

    PedsQL 4.0 is a validated tool used to assess health-related quality of life in children and adolescents aged 12 to 17 years (for subjects aged 12 years the PedsQL-Child will be used, for participants aged 13-17 years the PedsQL-Teen will be used). It evaluates four key domains: physical functioning, emotional well-being, social interactions, and school performance. It includes 23 items, each item is rated on a 5-point scale, with scores ranging from 0 to 100.

    Time frame: Screening to 24 months

  11. Changes over time on quality of life using EuroQol 5-Dimension five-level (EQ-5D-5L)

    EQ-5D-5L, a self-administered, generic preference-based measure that enables health utility estimation for economic evaluation. The EQ-5D-5L includes single items such as mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Patients provide their response to each item using a 5-category rating scale (no problems, slight problems, moderate problems, severe problems, and extreme problems). Patient responses to the items are used to derive utility values for the calculation of Quality-Adjusted Life-Years in economic modelling in health technology assessment. The visual analog scale (VAS) item on the EQ-5D-5L asks patients to rate how good or bad their health is today. It is a vertical thermometer with the anchors "best imaginable health" at 100 and the "worst imaginable health" at 0.

    Time frame: 24 months

  12. Quantitation of T, B, and natural killer (NK) cells and total lymphocytes in peripheral blood (PB) pre- and post-CLLS52 administration

    Time frame: UCART22 infusion to Day 84

  13. Monitoring of anti-alemtuzumab (CLLS52) antibodies in serum pre- and post-administration of CLLS52

    Time frame: Screening to Day 84

07

Study locations

20 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Sep 2026, 83 months.

Of 50 phase 1/2 interventional studies under Burkitt Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 114. This study's 83 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Jun 2026 → Sep 2026 and completion Jun 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2019
First posted
Nov 4, 2019
StartActual
Oct 14, 2019
Primary completionActual
Sep 16, 2026was Jun 2026
CompletionEst.
Dec 2027was Jun 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 9, 2026
Sites
17 sites added, 16 sites removed
Show 17 added (12 United States, 5 France)
  • Children's of Alabama · Birmingham, United States
  • University of California Los Angeles (UCLA) · Los Angeles, United States
  • UCSF Benioff Children's Hospital · San Francisco, United States
  • UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center · Aurora, United States
  • SCRI - Colorado Blood Cancer Institute · Denver, United States
  • University of Illinois Medical Center · Chicago, United States
  • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care · New York, United States
  • SCRI - TriStar Centennial Medical Center · Nashville, United States
  • SCRI - St. David's South Austin Medical Center · Austin, United States
  • University of Texas MD Anderson Cancer Center · Houston, United States
  • Methodist Hospital - San Antonio · San Antonio, United States
  • University of Wisconsin - Madison · Madison, United States
  • Centre Hospitalier Universitaire Nantes - Hôtel Dieu · Nantes, France
  • Hôpital Saint-Louis · Paris, France
  • Hôpital Robert-Debré AP-HP · Paris, France
  • Centre Hospitalier Lyon-Sud · Pierre-Bénite, France
  • Hôpital Pontchaillou · Rennes, France
Show 16 removed
  • University of California, Los Angeles (UCLA) - Medical Center · Los Angeles, United States
  • University of Colorado - Aurora Cancer Center · Aurora, United States
  • Sarah Cannon - Colorado Blood Cancer Institute · Denver, United States
  • University of Chicago · Chicago, United States
  • Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center · New York, United States
  • Weill Medical College of Cornell University · New York, United States
  • Sarah Cannon - HCA Research Institute · Nashville, United States
  • Sarah Cannon - St. David's South Austin Medical Center · Austin, United States
  • MD Anderson Cancer Center · Houston, United States
  • Sarah Cannon - Texas Transplant Institute at Methodist Hospital · San Antonio, United States
  • University of Wisconsin Carbone Cancer Center · Madison, United States
  • CHU de Nantes - Hôtel-Dieu · Nantes, France
  • Hôpital Saint Louis, Unité d'Hématologie Adolescents et Jeunes Adultes Département d'Hématologie · Paris, France
  • Hôpital Robert Debré - Service d'hémato-immunologie · Paris, France
  • Hôpital Lyon Sud · Pierre-Bénite, France
  • CHU Rennes - Hopital Pontchaillou · Rennes, France
Nov 9, 2026
Primary completion
Jun 30, 2026→Sep 16, 2026 (actual)
Nov 9, 2026
Study completion
Jun 30, 2026→Dec 2027
Nov 9, 2026
Enrollment
52 (estimated)→45 (actual)
Nov 9, 2026
Eligibility
Minimum age 15 Years→12 Years; Criteria largely rewritten (15 changes)
What changed in the criteria
Inclusion criteria
  • RemovedB-ALL blast cells expressing CD22
  • RemovedDiagnosed with R/R B-ALL
  • RemovedPrior therapy must include at least one standard chemotherapy regimen and at least one salvage regimen
  • AddedMust have measurable or evaluable disease in the bone marrow (BM) of at least 5% blasts at the time of enrollment
  • AddedReceived prior autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy (unless participants were not able to receive prior autologous anti-CD19 CAR T-cell therapy or if autologous anti-CD19 CAR T-cell therapy has not been available due to any reason or documented as CD19 negative relapsed or refractory B-ALL.
  • AddedCohort A:
  • Added- At least 70% of B-ALL blast cells must express CD22 by flow cytometry performed as per standard practice
  • AddedCohort B:
  • Added- Less than 70% of B-ALL blast cells must express CD22 by flow cytometry performed as per standard practice
Exclusion criteria
  • Removed-Prior cellular therapy or investigational cellular or gene therapy within 90 days prior to enrollment
  • AddedPrior CD22 CAR-T cell therapy
  • AddedMore than 1 allogenic hematopoietic stem cell transplant (HSCT)
  • AddedActive, acute, or chronic graft-versus-host disease (GvHD)
  • AddedWhite blood cell (WBC) count ≥ 50,000 cells/μL at Screening or rapidly progressive disease (PD) that, in the estimation of the Investigators and Sponsor, would compromise ability to complete study therapy
  • AddedRadiologically detected central nervous system (CNS) leukemia or CNS-3 disease
Nov 9, 2026
Interventions
Arm changed Dose Escalation→UCART22
Nov 9, 2026
Primary outcomes
2 added, 2 removed
What changed in the outcomes
  • AddedIncidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) throughout the study in relation to UCART22 and/or lymphodepletionTime frame: 24 months
  • AddedPercentage of participants achieving a complete response (CR) or CR with incomplete hematologic recovery (CRi) according to the Response Criteria for acute lymphoblastic leukemia (ALL) assessed by independent response review committeeTime frame: Within 3 months at Day 28, Day 56, Day 84
  • RemovedIncidence of AE/SAE/DLT [Safety and Tolerability]Time frame: 24 Months
  • RemovedDose escalation part: Occurrence of Dose Limiting Toxicities (DLTs)Time frame: Up to D28 post initial UCART22 infusion
Nov 9, 2026
Secondary outcomes
3 time frame changed, 9 added, 1 removed
What changed in the outcomes
  • AddedNumber of participants who were transplant ineligible at trial start that transition to transplant eligible as assessed by the investigatorTime frame: UCART22 infusion to Day 84
  • AddedNumber of participants achieving minimal residual disease (MRD) negativityTime frame: Day 28, Day 42, Day 56, Day 84
  • AddedOverall Response Rate (ORR)Time frame: At 3 months (Day 28, Day 42, Day 56, Day 84) as defined by National Comprehensive Cancer Network (NCCN) guidelines
  • AddedMolecular MRD-negative event free survival (mEFS) rateTime frame: At 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months
  • AddedChanges over time on quality of life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (adults)Time frame: 24 months
  • AddedChanges over time on quality of life using Pediatric Quality of Life Inventory (PedsQL) 4.0 (12-17 years)Time frame: Screening to 24 months
  • AddedChanges over time on quality of life using EuroQol 5-Dimension five-level (EQ-5D-5L)Time frame: 24 months
  • AddedQuantitation of T, B, and natural killer (NK) cells and total lymphocytes in peripheral blood (PB) pre- and post-CLLS52 administrationTime frame: UCART22 infusion to Day 84
  • AddedMonitoring of anti-alemtuzumab (CLLS52) antibodies in serum pre- and post-administration of CLLS52Time frame: Screening to Day 84
  • RemovedInvestigator assessed overall response rate according to the Response criteria for Acute Lymphoblastic Leukemia (ALL)Time frame: At Day 28, Day 56, Day 84, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21 and Month 24
  • Time frameDuration of ResponseFrom the date of the initial response to the date of disease progression or death from any cause, whichever occurs first, assessed up to Month 24 → From the date of the initial response to the date of disease progression or death from any cause, whichever occurs first, assessed up to 24 months4
  • Time frameProgression Free SurvivalFrom the first day of study treatment to the date of disease progression or death from any cause, whichever occurs first, assessed up to Month 24 → From the first day of trial treatment to the date of disease progression or death from any cause, whichever occurs first, assessed up to 24 months
  • Time frameOverall SurvivalFrom the first day of study treatment to the date of death from any cause, assessed up to Month 24 → From the first day of trial treatment to the date of death from any cause, assessed up to 24 months
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Recruiting→Active, not recruiting
    17 sites added, 16 sites removed
    Show 17 added (12 United States, 5 France)
    • Children's of Alabama · Birmingham, United States
    • University of California Los Angeles (UCLA) · Los Angeles, United States
    • UCSF Benioff Children's Hospital · San Francisco, United States
    • UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center · Aurora, United States
    • SCRI - Colorado Blood Cancer Institute · Denver, United States
    • University of Illinois Medical Center · Chicago, United States
    • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care · New York, United States
    • SCRI - TriStar Centennial Medical Center · Nashville, United States
    • SCRI - St. David's South Austin Medical Center · Austin, United States
    • University of Texas MD Anderson Cancer Center · Houston, United States
    • Methodist Hospital - San Antonio · San Antonio, United States
    • University of Wisconsin - Madison · Madison, United States
    • Centre Hospitalier Universitaire Nantes - Hôtel Dieu · Nantes, France
    • Hôpital Saint-Louis · Paris, France
    • Hôpital Robert-Debré AP-HP · Paris, France
    • Centre Hospitalier Lyon-Sud · Pierre-Bénite, France
    • Hôpital Pontchaillou · Rennes, France
    Show 16 removed
    • University of California, Los Angeles (UCLA) - Medical Center · Los Angeles, United States
    • University of Colorado - Aurora Cancer Center · Aurora, United States
    • Sarah Cannon - Colorado Blood Cancer Institute · Denver, United States
    • University of Chicago · Chicago, United States
    • Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center · New York, United States
    • Weill Medical College of Cornell University · New York, United States
    • Sarah Cannon - HCA Research Institute · Nashville, United States
    • Sarah Cannon - St. David's South Austin Medical Center · Austin, United States
    • MD Anderson Cancer Center · Houston, United States
    • Sarah Cannon - Texas Transplant Institute at Methodist Hospital · San Antonio, United States
    • University of Wisconsin Carbone Cancer Center · Madison, United States
    • CHU de Nantes - Hôtel-Dieu · Nantes, France
    • Hôpital Saint Louis, Unité d'Hématologie Adolescents et Jeunes Adultes Département d'Hématologie · Paris, France
    • Hôpital Robert Debré - Service d'hémato-immunologie · Paris, France
    • Hôpital Lyon Sud · Pierre-Bénite, France
    • CHU Rennes - Hopital Pontchaillou · Rennes, France
    Primary completion Jun 30, 2026→Sep 16, 2026 (now actual)
    Study completion Jun 30, 2026→Dec 2027
    Enrollment 52 (estimated)→45 (actual)
    Eligibility Minimum age 15 Years→12 Years; Criteria largely rewritten (15 changes)
    What changed in the criteria
    Inclusion criteria
    • RemovedB-ALL blast cells expressing CD22
    • RemovedDiagnosed with R/R B-ALL
    • RemovedPrior therapy must include at least one standard chemotherapy regimen and at least one salvage regimen
    • AddedMust have measurable or evaluable disease in the bone marrow (BM) of at least 5% blasts at the time of enrollment
    • AddedReceived prior autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy (unless participants were not able to receive prior autologous anti-CD19 CAR T-cell therapy or if autologous anti-CD19 CAR T-cell therapy has not been available due to any reason or documented as CD19 negative relapsed or refractory B-ALL.
    • AddedCohort A:
    • Added- At least 70% of B-ALL blast cells must express CD22 by flow cytometry performed as per standard practice
    • AddedCohort B:
    • Added- Less than 70% of B-ALL blast cells must express CD22 by flow cytometry performed as per standard practice
    Exclusion criteria
    • Removed-Prior cellular therapy or investigational cellular or gene therapy within 90 days prior to enrollment
    • AddedPrior CD22 CAR-T cell therapy
    • AddedMore than 1 allogenic hematopoietic stem cell transplant (HSCT)
    • AddedActive, acute, or chronic graft-versus-host disease (GvHD)
    • AddedWhite blood cell (WBC) count ≥ 50,000 cells/μL at Screening or rapidly progressive disease (PD) that, in the estimation of the Investigators and Sponsor, would compromise ability to complete study therapy
    • AddedRadiologically detected central nervous system (CNS) leukemia or CNS-3 disease
    Primary outcomes 2 added, 2 removed
    What changed in the outcomes
    • AddedIncidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) throughout the study in relation to UCART22 and/or lymphodepletionTime frame: 24 months
    • AddedPercentage of participants achieving a complete response (CR) or CR with incomplete hematologic recovery (CRi) according to the Response Criteria for acute lymphoblastic leukemia (ALL) assessed by independent response review committeeTime frame: Within 3 months at Day 28, Day 56, Day 84
    • RemovedIncidence of AE/SAE/DLT [Safety and Tolerability]Time frame: 24 Months
    • RemovedDose escalation part: Occurrence of Dose Limiting Toxicities (DLTs)Time frame: Up to D28 post initial UCART22 infusion
    Secondary outcomes 3 time frame changed, 9 added, 1 removed
    What changed in the outcomes
    • AddedNumber of participants who were transplant ineligible at trial start that transition to transplant eligible as assessed by the investigatorTime frame: UCART22 infusion to Day 84
    • AddedNumber of participants achieving minimal residual disease (MRD) negativityTime frame: Day 28, Day 42, Day 56, Day 84
    • AddedOverall Response Rate (ORR)Time frame: At 3 months (Day 28, Day 42, Day 56, Day 84) as defined by National Comprehensive Cancer Network (NCCN) guidelines
    • AddedMolecular MRD-negative event free survival (mEFS) rateTime frame: At 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months
    • AddedChanges over time on quality of life using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) (adults)Time frame: 24 months
    • AddedChanges over time on quality of life using Pediatric Quality of Life Inventory (PedsQL) 4.0 (12-17 years)Time frame: Screening to 24 months
    • AddedChanges over time on quality of life using EuroQol 5-Dimension five-level (EQ-5D-5L)Time frame: 24 months
    • AddedQuantitation of T, B, and natural killer (NK) cells and total lymphocytes in peripheral blood (PB) pre- and post-CLLS52 administrationTime frame: UCART22 infusion to Day 84
    • AddedMonitoring of anti-alemtuzumab (CLLS52) antibodies in serum pre- and post-administration of CLLS52Time frame: Screening to Day 84
    • RemovedInvestigator assessed overall response rate according to the Response criteria for Acute Lymphoblastic Leukemia (ALL)Time frame: At Day 28, Day 56, Day 84, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21 and Month 24
    • Time frameDuration of ResponseFrom the date of the initial response to the date of disease progression or death from any cause, whichever occurs first, assessed up to Month 24 → From the date of the initial response to the date of disease progression or death from any cause, whichever occurs first, assessed up to 24 months4
    • Time frameProgression Free SurvivalFrom the first day of study treatment to the date of disease progression or death from any cause, whichever occurs first, assessed up to Month 24 → From the first day of trial treatment to the date of disease progression or death from any cause, whichever occurs first, assessed up to 24 months
    • Time frameOverall SurvivalFrom the first day of study treatment to the date of death from any cause, assessed up to Month 24 → From the first day of trial treatment to the date of death from any cause, assessed up to 24 months
    Interventions Arm changed Dose Escalation→UCART22
    + 3 other changes: verification date, description and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04150497
Lead sponsor
Cellectis S.A.
Responsible party
Sponsor
First posted
Nov 4, 2019
Start date
Oct 14, 2019
Primary completion
Sep 16, 2026
Completion
Dec 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Nitin Jain, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion